(19)
(11) EP 1 432 709 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.11.2005 Bulletin 2005/44

(45) Mention of the grant of the patent:
27.07.2005 Bulletin 2005/30

(21) Application number: 02798231.3

(22) Date of filing: 13.09.2002
(51) International Patent Classification (IPC)7: C07D 471/04, A61P 35/00
(86) International application number:
PCT/US2002/029154
(87) International publication number:
WO 2003/022846 (20.03.2003 Gazette 2003/12)

(54)

1-GLYOXYLAMIDE INDOLIZINES FOR TREATING CANCER

1-GLYOXYLAMIDINDOLIZINE ZUR BEHANDLUNG VON KREBS

INDOLIZINES DE 1-GLYOXYLAMIDE PERMETTANT DE TRAITER LE CANCER

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 13.09.2001 US 322020 P

(43) Date of publication of application:
30.06.2004 Bulletin 2004/27

(60) Divisional application:
05016203.1

(73) Proprietor: Synta Pharmaceuticals Corporation
Lexington, MA 02421 (US)

(72) Inventors:
  • KOYA, Keizo
    Chestnut Hill, MA 02467 (US)
  • SUN, Lijun
    Harvard, MA 01451 (US)
  • ONO, Mitsunori
    Lexington, MA 02421 (US)
  • YING, Weiwen
    Ayer, MA 01432 (US)
  • LI, Hao
    Brookline, MA 02446 (US)

(74) Representative: Luderschmidt, Schüler & Partner GbR 
Patentanwälte, John-F.-Kennedy-Strasse 4
65189 Wiesbaden
65189 Wiesbaden (DE)


(56) References cited: : 
GB-A- 2 287 706
 US-B1- 6 214 855
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).